Amylyx stock ( NASDAQ:AMLX ) crashed Friday, losing almost all of its value, after the company said its approved ALS treatment, Relyvrio, failed in a pivotal study. Patients who received Amylyx Pharmaceuticals' ( NASDAQ:AMLX ) Relyvrio showed no significant difference across multiple markers measuring the severity of amyotrophic lateral sclerosis, the longhand...
Price in a clear uptrend and RSI trend bullish, I'm expecting the price to break the Ichimoku cloud. Areas plotted to look out for, combined with moving averages.
As per the chat - Recent ish IPO Closed at an all time high of 32.95 in march Broke this high up to 38.65 Retested the 32.95 level and looks to be moving higher off this level. Tight stop in place as always!!
Hi again, I see that you are back near buy point. I'll buy if the price breaks above this range at $31.50 and add more once breaks to a new all time high at $34. The stock highly volatile, so I suggest starting with small positions and/or staggered stops.
ALMX has broken out of this strong down channel in red It has re entered a prior up channel that is looking to break to the upside This prior up channel will lead AMLX to its bullish potential (likely even breaking out of the channel)
Amylyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which provides disease-modifying solutions for neurodegenerative diseases. The firm focuses on streamlined clinical development and drug discovery. It specializes in developing a proprietary therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases that target the...
The health care industry is being leading the charge, NASDAQ:AMLX is the proof of that. This recent IPO just broke out of a good looking cup & handle pattern. Also, IBD is giving a 99 relative strength rating. So, I enter today with a small position. A "pilot position", as Mark Minervini would say. The market is still under pressure so I'm testing it. As this...